Pharmacology of Azimilide Dihydrochloride (NE‐10064), A Class III Antiarrhythmic Agent
Authors:
- 1 June 1997
- journal article
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 15 (2) , 137-156
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The SWORD of DamoclesThe Lancet, 1996
- K+ Channel Blockade in the Prevention of Ventricular Fibrillation in Dogs with Acute Ischemia and Enhanced Sympathetic ActivityJournal of Cardiovascular Pharmacology, 1995
- Effects of channel modulation and pH on IsK inhibition by the novel class III antiarrhythmic azimilide (NE-10064)European Journal of Pharmacology: Molecular Pharmacology, 1995
- ABSTRACT SESSION 39: BASIC IV: ION CHANNELS AND DRUGSPacing and Clinical Electrophysiology, 1995
- ABSTRACT SESSION 25: K+ CHANNEL BLOCKERS AND ARRHYTHAUASPacing and Clinical Electrophysiology, 1994
- Protection Against Programmed Electrical Stimulation-Induced Ventricular Tachycardia and Sudden Cardiac Death by NE-10064, a Class III Antiarrhythmic DrugJournal of Cardiovascular Pharmacology, 1993
- Safety and Toxicity of Antiarrhythmic Drug TherapyJournal of Cardiovascular Pharmacology, 1991
- Antiarrhythmic Treatment of Atrial ArrhythmiasJournal of Cardiovascular Pharmacology, 1991
- Current Classification of Antiarrhythmic Drugs as a Guide to Their Rational Clinical UseDrugs, 1986
- Dantrolene sodium: Effects on isolated cardiac tissuesJournal of Molecular and Cellular Cardiology, 1983